Peptides explained
CJC-1295: how it works
Also known as: DAC and no-DAC naming distinctions
Page updated · Sources and editorial approach
CJC-1295 explained: GHRH signalling, the DAC modification, early human hormone findings and why no-DAC labels need separate identification.
CJC-1295 at a glance
What it does biologically
The studied long-acting analogue stimulates growth-hormone release, with downstream changes in IGF-1.
What the evidence shows
Small early trials measured hormone concentrations and pharmacokinetics, not established anti-ageing or bodybuilding outcomes.
What remains uncertain
A product called CJC-1295 no DAC may refer to a different GHRH analogue. Evidence must match the sequence and modification.
The basics
What is CJC-1295?
CJC-1295 is a growth hormone-releasing hormone analogue developed to prolong hormone stimulation. Its drug-affinity-complex, or DAC, modification is central to the long-acting molecule studied in early human trials.
The commercial term 'CJC-1295 no DAC' is commonly used for modified GRF(1–29). Do not assume it has the same pharmacokinetics or evidence as the DAC-containing molecule. A name comparison is not an identity test.
Biological action
How does CJC-1295 work?
GHRH signalling stimulates the pituitary to release growth hormone, which can increase circulating IGF-1. This is upstream endocrine stimulation rather than direct replacement with growth hormone or IGF-1 LR3.
Early placebo-controlled studies in healthy adults measured GH and IGF-1 over days and weeks. Higher hormone levels demonstrate pharmacological activity; they do not establish better strength, recovery, sleep or longevity.
Questions being investigated
What do studies examine?
Hormone response
Early studies measured circulating growth hormone and IGF-1.
Duration of activity
The DAC modification changes persistence and is relevant to interpreting pharmacokinetic findings.
Naming and mixtures
No-DAC preparations and CJC/ipamorelin blends require their own identity and evidence assessment.
Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | GHRH-receptor activity underlies the hormone-release mechanism. |
| Animal | Experimental development is not evidence for a commercial blend. |
| Human | Two early placebo-controlled trials ran for 28 and 49 days and examined hormone responses in healthy adults. |
| Regulatory | An early hormone-response study is not an authorisation for anti-ageing or performance use. |
Important context
Risks, limitations and unanswered questions
- Short studies cannot settle long-term endocrine safety.
- Hormone concentrations are surrogate measurements, not proof of functional benefits.
- DAC and no-DAC evidence should not be interchanged.
- Combining CJC-related material with ipamorelin introduces a separate evidence question.
Reading the original evidence
A hormone response is a pharmacodynamic result
The human trials measured GH and IGF-I responses and pharmacokinetics over limited follow-up. Those are different outcomes from improved strength, injury recovery or longer-term health. A changed hormone concentration does not automatically prove a desirable clinical effect.
Question to take to the source: Does the paper report hormone exposure, or a clinical benefit measured directly in the relevant population?
Check the original source ↗For personal accounts and research questionnaires, read user feedback and patient-reported outcomes.
Questions answered
CJC-1295 FAQs
What is DAC?
It means drug-affinity complex, a modification associated with the studied molecule's longer persistence.
Does higher IGF-1 prove more muscle?
No. A hormone measurement does not establish strength, body-composition benefits or acceptable risk.
Is no DAC the same molecule?
Do not assume so. Confirm the exact sequence and modification.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- Teichman et al. (2006): CJC-1295 human trials ↗Primary placebo-controlled trials of hormone responses and pharmacokinetics; not a performance trial.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.